{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vergote I"],"funding":["Intramural NIH HHS","NCI NIH HHS"],"pagination":["e374-e384"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9465953"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(8)"],"pubmed_abstract":["The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active delib"],"journal":["The Lancet. Oncology"],"pubmed_title":["Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup."],"pmcid":["PMC9465953"],"funding_grant_id":["K08 CA234333","Z99 CA999999"],"pubmed_authors":["Chang TC","Cibula D","Bruchim I","Katsaros D","Mukhopadhyay A","Coronado P","Enomoto T","Scambia G","Berek J","Marth C","Bjorge L","Votan B","Rauh-Hain A","Davis A","Lee JM","McNeish I","Dorigo O","Sehouli J","Pignata S","Ottevanger N","Lorusso D","Poveda A","Carey M","Lok C","participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research","Tan DSP","Michel D","Ray-Coquard I","Vandecaveye V","Keller M","Welch S","Lu K","Gomez-Garcia EM","Berger R","Stuart G","Lopez-Zavala C","Kurtz JE","Ochiai K","Reuss A","Kohn EC","Colombo N","Boere I","Gourley C","Oda K","Braicu E","Kridelka F","Bookman M","Heinzelmann V","Auranen A","Roxburgh P","Joly F","Concin N","Nicum S","Oaknin A","Dundr Path P","Grimm C","Arend R","Mirza MR","Del Pilar Estevez Diz M","Paoletti X","Hasegawa K","Berek JS","Gonzalez Martin A","Bookman MA","Saadeh A","Oza AM","Denys H","Ng J","Kohn E","Okamoto A","Tsoref D","Gebski V","MacKay H","Kim HS","Vergote I","Stuart GCE","Cancido Dos Reis FJ","Zang R","Fujiwara H","Lee JY","Tan DS","Moore K","Glasspool R","O'Donnell D","Fujiwara K","Perez Fidalgo A","Herrington CS","Zhu J","Mahner S","Farrelly L","Gonzalez-Martin A","Beale P","du Bois A"],"additional_accession":[]},"is_claimable":false,"name":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.","description":"The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active delib","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-05T11:48:10.705Z","creation":"2025-04-05T11:48:10.705Z"},"accession":"S-EPMC9465953","cross_references":{"pubmed":["35901833"],"doi":["10.1016/S1470-2045(22)00139-5","10.1016/s1470-2045(22)00139-5"]}}